Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophrenia

Posted on by wpadmin
Teva Canada"s facility in Markham, Ontario, Canada.

JHVEPhoto/iStock Editorial via Getty Images

  • The pivotal clinical phase 3 trial for the olanzapine Long-Acting Injectable in schizophrenia has been completed, Medincell’s partner Teva Pharmaceuticals (NYSE:TEVA) said, who finances and pilots the regulatory development of the product (mdc-TJK / TEV-‘749).
  • Medincell to receive a $5 million

Leave a Reply

Your email address will not be published. Required fields are marked *